Duchenne muscular dystrophy (DMD) is a severe, progressive disease that affects 1 in 3600–6000
live male births. Although guidelines are available for various aspects of DMD, …

Since the publication of the Duchenne muscular dystrophy (DMD) care considerations in
2010, multidisciplinary care of this severe, progressive neuromuscular disease has evolved. In …

Optimum management of Duchenne muscular dystrophy (DMD) requires a multidisciplinary
approach that focuses on anticipatory and preventive measures as well as active …

Background Isocitrate dehydrogenase (IDH)–mutant grade 2 gliomas are malignant brain
tumors that cause considerable disability and premature death. Vorasidenib, an oral brain-…

Background The estimation of risk of recurrence for patients with colon carcinoma must be
improved. A robust immune score quantification is needed to introduce immune parameters …

Background Isocitrate dehydrogenase 1 (IDH1) mutations occur in approximately 13% of
patients with intrahepatic cholangiocarcinoma, a relatively uncommon cancer with a poor …

Background The combination of ivosidenib — an inhibitor of mutant isocitrate dehydrogenase
1 (IDH1) — and azacitidine showed encouraging clinical activity in a phase 1b trial …

Background 18% of the world's population lives in India, and many states of India have
populations similar to those of large countries. Action to effectively improve population health in …

… included in the article’s Creative Commons license, unless indicated otherwise in a credit
line to the material. If material is not included in the article’s Creative Commons license and …

We performed a randomized, double-blind, controlled six-month trial of prednisone in 103
boys with Duchenne's muscular dystrophy (age, 5 to 15 years). The patients were assigned to …